CINECA IRIS Institutional Research Information System

GALIMBERTI, SARA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 41.039
AS - Asia 18.179
EU - Europa 14.800
SA - Sud America 3.144
Continente sconosciuto - Info sul continente non disponibili 974
AF - Africa 666
OC - Oceania 38
Totale 78.840
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 37.623
SG - Singapore 5.354
CN - Cina 5.188
IT - Italia 5.182
HK - Hong Kong 3.246
CA - Canada 3.116
BR - Brasile 2.601
SE - Svezia 2.401
VN - Vietnam 1.677
DE - Germania 1.190
BG - Bulgaria 1.145
PL - Polonia 1.033
GB - Regno Unito 833
TR - Turchia 710
FR - Francia 674
RU - Federazione Russa 595
FI - Finlandia 568
UA - Ucraina 444
IN - India 390
JP - Giappone 388
KR - Corea 292
CI - Costa d'Avorio 211
CH - Svizzera 202
BD - Bangladesh 181
AR - Argentina 159
MX - Messico 122
IQ - Iraq 112
NL - Olanda 99
EC - Ecuador 96
BE - Belgio 88
ID - Indonesia 88
SN - Senegal 87
AT - Austria 85
PK - Pakistan 83
ZA - Sudafrica 83
UZ - Uzbekistan 82
SA - Arabia Saudita 74
CO - Colombia 64
VE - Venezuela 56
PY - Paraguay 53
ES - Italia 52
MA - Marocco 52
KE - Kenya 46
NG - Nigeria 44
EG - Egitto 38
PH - Filippine 35
CL - Cile 33
CR - Costa Rica 32
UY - Uruguay 31
MY - Malesia 30
PE - Perù 30
AU - Australia 29
CZ - Repubblica Ceca 29
IE - Irlanda 29
IL - Israele 27
JM - Giamaica 27
AZ - Azerbaigian 25
LT - Lituania 23
TN - Tunisia 22
JO - Giordania 21
RO - Romania 20
AE - Emirati Arabi Uniti 19
GR - Grecia 19
KZ - Kazakistan 19
OM - Oman 19
BJ - Benin 18
DO - Repubblica Dominicana 18
TT - Trinidad e Tobago 18
BO - Bolivia 17
EU - Europa 16
PS - Palestinian Territory 16
NP - Nepal 15
ET - Etiopia 14
NI - Nicaragua 14
DZ - Algeria 13
HN - Honduras 13
PT - Portogallo 13
AL - Albania 10
DK - Danimarca 10
IR - Iran 10
LB - Libano 10
BB - Barbados 9
HU - Ungheria 9
PA - Panama 9
TH - Thailandia 9
NZ - Nuova Zelanda 8
RS - Serbia 8
SC - Seychelles 8
BH - Bahrain 7
BY - Bielorussia 7
GT - Guatemala 7
TW - Taiwan 7
GE - Georgia 6
PR - Porto Rico 6
EE - Estonia 5
KG - Kirghizistan 5
KW - Kuwait 5
MD - Moldavia 5
SV - El Salvador 5
SY - Repubblica araba siriana 5
Totale 77.781
Salva come PNG Salva come JPEG
Città #
Ashburn 3.793
Hong Kong 3.199
Woodbridge 3.154
Singapore 2.988
Fairfield 2.510
Dallas 2.474
Ann Arbor 2.393
Montreal 2.351
Houston 2.016
Serra 2.009
San Jose 1.889
Chandler 1.810
Santa Clara 1.717
Milan 1.252
Beijing 1.185
Shanghai 1.155
Sofia 1.137
Seattle 1.102
Wilmington 869
New York 864
Cambridge 823
Council Bluffs 714
Boardman 683
Princeton 630
Ottawa 593
Jacksonville 572
Los Angeles 562
Lawrence 454
Medford 437
Ho Chi Minh City 434
Lauterbourg 433
Hefei 424
Izmir 424
Tokyo 342
Nanjing 315
Seoul 275
Hanoi 256
Florence 232
Des Moines 231
São Paulo 224
London 221
Abidjan 210
Istanbul 203
Munich 202
Dearborn 198
Buffalo 186
Redondo Beach 185
Dong Ket 169
San Diego 169
Rome 168
Bern 159
Nanchang 155
Helsinki 139
Redwood City 120
Frankfurt am Main 113
Chicago 105
Atlanta 100
Jüchen 98
Bremen 94
Pisa 92
Orem 90
Hebei 88
Lancaster 88
Dakar 87
Brussels 86
Changsha 86
Shenyang 84
Rio de Janeiro 81
Tashkent 75
Kunming 73
Ogden 69
Turku 68
Fuzhou 67
Phoenix 66
Columbus 63
Nuremberg 63
Vienna 63
Da Nang 61
The Dalles 58
Belo Horizonte 56
Toronto 56
Denver 55
Düsseldorf 54
Guangzhou 52
Curitiba 51
San Francisco 51
Boulder 49
Brooklyn 48
Jiaxing 48
Westminster 48
Dhaka 46
Chennai 45
Haiphong 45
Porto Alegre 45
Norwalk 44
Warsaw 44
Washington 44
Hangzhou 42
Pune 42
Baghdad 41
Totale 54.433
Salva come PNG Salva come JPEG
Nome #
EFFICACY AND TOXICITY PROFILES OF LOW-DOSE THALIDOMIDE AS MAINTENANCE THERAPY IN MULTIPLE MYELOMA PATIENTS AFTER DOUBLE OR TRIPLE AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION. 3.419
Diagnostic applications of nuclear medicine: Multiple myeloma 761
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 444
Prognostic Impact of TS, MTHFR and XRCC1 Genetic Variants in 113 Patients with Myelodysplastic Syndromes 282
Multidisciplinary Evaluation Improves Efficacy and Safety of Iron Chelation Therapy with Deferasirox in MDS Elderly Patients 270
Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA 267
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 255
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 252
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 250
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 240
Mesenchymal cells inhibit expansion but not cytotoxicity exerted by gamma-delta T cells 238
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 235
Correspondence between salivary proteomic pattern and clinical course in primary Sjogren syndrome and non-Hodgkin's lymphoma: a case report 232
IN THE CHRONIC MYELOID LEUKEMIA THE SALIVARY PROTEOMICS RECAPITULATES SOME ASPECTS OF THE LEUKEMIC STEM CELL. LA CELLULA STAMINALE LEUCEMICA E LA PROTEOMICA SALIVARE: IL MODELLO DELLA LEUCEMIA MIELOIDE CRONICA 232
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases 231
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 226
Expression of MDR1, MRP, TOPOISOMERASE-IIa, TOPOISOMERASE-IIb and GSTp in acute leukemias. 223
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 222
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 221
MESENCHYMAL CELLS INHIBIT IL2 AND ZOLENDRONATE-INDUCED ?/d T-LYMPHOCYTES 219
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 219
ED-B fibronectin expression is a marker of epithelial-mesenchymal transition in translational oncology 218
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 218
An Automated Cartridge-Based Microfluidic System for Real-Time Quantification of BCR::ABL1 Transcripts in Chronic Myeloid Leukemia: An Italian Experience 215
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 215
Autoimmune diseases and myeloid hematological disorders: a possible pathogenetic relationship 215
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 213
Panobinostat for the treatment of acute myelogenous leukemia 211
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 210
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 209
WT1 GENE EXPRESSION IS SIGNIFICANTLY INHIBITED BY VORINOSTAT AND BORTEZOMIB IN MYELOPROLIFERATIVE/MYELODISPLASTIC DISEASES 208
5-AZACYTIDINE FOR THE TREATMENT OF INTERMEDIATE-2/HIGH IPSS RISK MYELODYSPLASTIC SYNDROMES: RESULTS IN 83 PATIENTS FROM THE ITALIAN PATIENT NAMED PROGRAM 208
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 207
Clinical Applications of Nuclear Medicine: Multiple Myeloma 207
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 207
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 207
EXTENSIVE ANALYSIS OF T CELL RECEPTOR GAMMA (TCRG) GENE REARRANGEMENTS REVEALS A SIMILAR REPERTOIRE IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) AND IN HYPEREOSINOPHILIC SYNDROME (HES) 206
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real‐Life Italian Multicenter Harmonization Experience 205
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 205
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 205
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 204
The c.480C>G polymorphism of hOCT1 influences imatinib clearance in patients affected by chronic myeloid leukemia. 204
Characterization of Ph-negative abnormal clones emerging during imatinib therapy 203
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 201
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 200
Oral cyclophosphamide therapy for patients with residual or relapsed indolent-type lymphoma after initial treatment for aggressive lymphomas. A sub-group of patients with apparent transformed indolent lymphoma. 200
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 200
The Role of Microenvironment in Bispecific Antibodies Treatment in Multiple Myeloma 199
Real‐world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study 199
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 199
Carboxy-terminal fragment of osteogenic growth peptide regulates myeloid differentiation through RhoA 199
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 197
Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351 197
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 197
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 197
Diagnostic Applications of Nuclear Medicine: Leukemias 197
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 197
Unexpected cardiotoxicity in haematological bortezomib treated patients 196
GTF2I mutations are common in thymic epithelial tumors but not in hematological malignancies 196
PS-341 (Bortezomid) inhibits both proliferation of megakaryoblastic cells in vitro and MK colonies production in patients affected by idiopathic myelofibrosis 194
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 193
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 193
Suspension of Bone Marrow-Derived Undifferentiated Mesenchymal Stromal Cells for Repair of Superficial Digital Flexor Tendon in Race Horses. Tissue Eng. 2007 Oct 5 192
SAHA INHIBITS PROLIFERATION AND INDUCES APOPTOSIS IN A MEGAKARYOBLASTIC CELL LINE AND SYNERGISTICALLY INTERCATCS WITH THE PORTEASOME INHIBITOR BORTEZOMIB. 191
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 191
Skin and stomach graft versus host disease after syngeneic BMT in CML: A case report., LEUKEMIA RESEARCH,pp 00,tot.pag 00,tot. autori 7,2007 191
Enhancement of hematopoietic stem cell engraftment by inhibition of CXCL12 proteolysis with sitagliptin, an oral dipeptidyl-peptidase IV inhibitor: a report in a case of delayed graft failure 191
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 191
Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment 191
Predictive role of WT1 and RPS14 expression in patients affected by myelodysplastic syndromes receiving azacitidine 190
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 190
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 189
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real‐World Study 188
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 188
Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 187
BENDAMUSTINE, BORTEZOMIB AND DEXAMETHASONE (BVD) COMBINATION FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: AN INTERIM ANALYSIS OF A PHASE II STAUDY. 187
MDS: An Integrated Workup for a Correct Diagnosis 187
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 187
ATP-binding cassette transmembrane transporters and their epigenetic control in cancer: an overview 187
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 186
Good manufacturing practice-grade fibrin gel is useful as a scaffold for human mesenchymal stromal cells and supports in vitro osteogenic differentiation 186
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 186
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 186
Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography. 185
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 185
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 185
Ficoll-hypaque separation vs whole blood lysis: Comparison of efficiency and impact on minimal residual disease analysis 185
90y Ibritumomab Tiuxetan as Initial Treatment for Follicular Lymphoma (ZEUS Protocol). An Italian Cooperative Study Group 184
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 184
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 184
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 183
SAFETY AND EFFICACY OF 90 Y IBRITUMUMAB TIUXETAN (ZEVALIN) FOR UNTREATED FOLLICULAR NON HODGKIN'S LYMPHOMA (FL) PATIENTS. ITALIAN MULTICENTRIC TRIAL. 183
Unusual morphology in a case of large granular cell leukemia 183
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis 183
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 183
Correction: Real-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia 181
No reactivation of JCV in bone marrow of follicular lymphoma patients treated front-line with rituximab plus 90y-ibritumomab tiuxetan 181
Torquetenovirus (TTV) load is associated with mortality in Italian elderly subjects 180
Precision medicine in lymphoma by innovative instrumental platforms 180
Gelatin/PLLA sponge-like scaffolds allow proliferation and osteogenic differentiation of human mesenchymal stromal cells 180
Totale 24.360
Salva come PNG Salva come JPEG
Categoria #
all - tutte 218.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 218.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.284 0 362 141 344 919 658 158 235 440 150 363 1.514
2022/20235.772 910 812 383 550 568 698 54 457 873 45 356 66
2023/20248.104 603 555 557 365 713 798 230 106 66 3.358 186 567
2024/202514.818 66 562 123 786 1.150 1.255 1.366 946 1.483 1.980 1.617 3.484
2025/202617.663 912 2.322 2.790 1.925 1.560 1.617 2.341 793 891 1.395 819 298
2026/20273.974 1.127 2.847 0 0 0 0 0 0 0 0 0 0
Totale 78.840